NCT04878471View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASP5354 in Healthy Adult Japanese Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 2, 2021

Primary Completion Date

July 22, 2021

Study Completion Date

July 22, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

Pudexacianinium chloride

Intravenous

DRUG

Placebo

Intravenous

Trial Locations (1)

Unknown

JP81001, Sumida-ku

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY